Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
how is this stock still listed? there has to be fraud here, no?
Toast...
"We are filing this registration statement with the Securities and Exchange Commission (the “SEC”) using a “shelf” registration process. Under this registered “shelf,” in the future, we may, from time to time, sell any combination of the securities described herein, in one or more offerings, up to a maximum aggregate offering price of $150,000,000. This prospectus provides you with a general description of the securities."
The PUMP / Fake stock analyst that was promoting the ex CEO and this garbage from when he bet the farm at $2750 pre split, maybe changing Zip Codes 😂
“ Following the issuance of pre-funded warrants having a value of $4.5 million to the lender, ”
IBIO sure got their ass handed to them just as I called it. That fake stock analyst that has been pumping the stock from $2750 all the way down to these levels is a con artist as he said the company was going to come out way ahead. He must think dilution is a good thing. What an imbecile.
If IBIO didn’t do the huge reverse splits, the share price would be something like $0.0002 LMAO.
IBIO PUMPER was illegally giving out financial advice to BUY BUY BUY this 💩 without a license. Heck, he cam’t even do simple math.
IBIO up 7% from traders that can’t read filings. When is the ticker tape parade lead by iBIO PUMP BOI who is down 99.99% from a whopping $2750 pre reverse split.
$2.45 HOD
When is the next reverse split for IBIO? That would make 4 in only a few years, right? Will they adjust the authorized shares this time along the RS ratio? Or keep authorized shares the same and make this a fantastic ATM machine for management, at the expense of shareholders? This investment is and has been a 💩 for a long time, although still recommended and purchased by some fake stock analysts with very poor investment track record. No zip code changes yet in that couple of decade long portfolio. 🙀
IBIO heading back down to the 52 week low because of massive dilution
Where's the IBIO stock pumper hiding?
IBIO could use a new stock analyst and pumper. The one that has been around for 4 years, pumped this all the way down from $2500 presplit to a buck and experienced catastrophic losses. Easy to short whatever he pumps.
this company could use a new management team, imo
NO VALUE!
Printing $1.67
The bell can’t get here soon enough.
IBIO analyst lost now 66% in his last buy while averaging down from $2500 and 99.99% loss on the nest egg and college fund.
Printing $1.80
When is the class action lawsuit against the stock analyst that was telling everyone to BUY BUY BUY from $2000+ presplit down to a buck WITHOUT any disclosures, licenses or even financial training other than managing a piggybank?
If enough people notify the SEC, they may raise it up on the priority list.
Got to know to hold them and fold them trader
MOO depression sucks
IBIO sell off. The stock analyst that is down 99.99% on this one guessed wrong yet AGAIN.
If one lost money following his investment advice on social media without any disclosures, you could not only report him to the SEC but file a nice case against him as I hear that is illegal.
Nothing but red.
https://ih.advfn.com/stock-market/AMEX/ibio-IBIO/trades
Printing $1.86
That is equivalent to $0.000372 presplits
$20K with of IBIO bought on July 28, 2020 now with $14.88 using 'simple math'
Not often you get to buy a stock at $5 because of multiple huge reverse splits. When is the 4th one coming? IBIO has a LOT of AS to dilute this to death.
Printing $1.92
I post how very few 'tutes' even own IBIO except for one that has been charged with naked shorting and the sp drops? I thought the IBIO stock analyst and others did proper DD?
Prolly should have mentioned of the 21 funds holding IBIO and 251,464 shares, Sabby Management has the majority of those at 176,748
https://www.holdingschannel.com/bystock/?symbol=IBIO
Shabby is a known short and SEC charged them with Naked Shorting. Oh what a surprise financial advisors getting charged.
SEC Charges Investment Adviser and Principal in Abusive Naked Short Selling Scheme - June 12, 2023
https://www.sec.gov/news/press-release/2023-107
It seems after they were charged, they started buying the stocks they 'apparently' shorted. Maybe a way to hedge their 'SEC charges' bets?
Basically subtract out Sabby, there are very little shares held by 'tutes' anymore. Maybe not as smittened by iBio's new CEO Dr. Martin Brenner?
https://fintel.io/i/sabby-management-llc
https://hedgefollow.com/funds/Sabby+Management
I get it. IBIO bagholder gambled the house at the stock peak and then bought even more every time IBIO popped and now is humiliate.
Even bought more at $4-ish he says not realizing there were 2 massive RS when he bought at $5 before
Can't undo foolishness
How's your hero Tommy doing? Unrequited love is a bitch.
Poor IBIO pumper stock analyst totally vexed and busted in lies
Said they didn't buy $20K of IBIO but whoops, there is the posts
Said they didn't average down on IBIO but whoops, there are dozens of those posts too
Said they didn't give out financial advice on IBIO but whoops there are plenty of the BUY BUY BUY posts
Just like when they said they didn't call into biotech conference calls pretending to be a stock analyst but whoops there are plenty of audio tapes
btw: Everything I've posted is public information actual shared by IBIO pumper stock analyst. Pumpers remorse LMAO
hey thanks for thinking of me being important enough to dox me brah
yeah Tom Isett - old news pal - sorry to inform yhee
need to keep up with the changing times Sporto
let me help you with that - here's some educatin from iBio's new CEO Dr. Martin Brenner:
Part 1
Tom's got all the right stuff?
Can't fix stupid
"been buying low 20's low to 30's waiting for the RS for next tranche"
Can't fix stupid
Either a liar, fraud or a really, really, really bad stock analyst.
Funny thing is next week...
they will deny it
Guess what $20K worth of IBIO is worth now IBIO BOI.
Peeps that give out financial advice on social media without disclosures and a license should be prosecuted to the full extend of the law no matter how dumb they are.
4 year bagholder. LMAO
"giving out"...?
"giving out" hot dogs - but then collecting or not collecting a fee for ones services...?
is that like a hot dog salesman on 42nd St and 2nd Ave in Manhattan - you know well - NYC eh Red
should one not be paid for eating a hot dog they bought ...?
no sales here pal - no iBio stock ownership either
and in herein lies a failed and poorly constructed public forum thesis- like that of a 2nd grader
nuff said - I ain't working to earn $0.05/post all day long pal....lolzzz
MOO bad brains
to answer your question no
you really need to get off the rag and go to law school
but hey good luck with your iBio holdings sporto
MOO bad brains
Another 2 posts giving out financial advice on social media to buy IBIO without a license.
Check the date. They were already dumping on noob IBIO investors heads even a year before.
Isn't touting stocks like IBIO and giving financial advise on social media without a disclosure or a license illegal?
IBIO Printing $1.8401
IBIO Little Pumper getting crushed from his all time high purchase of $1875 but just needs a 1000 bagger from here.
Used to be quite a few until IBIO started diluting so much had to do multiple reverse splits. Now all IBIO has is one little pumper than is down 99.9x%. Ouch!
Date Split Multiple Cumulative multiple
2023-11-29 1:20 x0.05 x0.0002
2022-10-10 1:25 x0.04 x0.004
2018-06-11 1:10 x0.1 x0.1
Institutional Ownership dropped 85% since then
The real story is when you look at the dollars
Institutions used to own $ 79,020,000. Now they own $341,000K
For those that are bad with 'simple math', that is about a 1/2 of 1%. Yikes!
Institutional Ownership and Shareholders 2021-03-31
185 total, 177 long only, 1 short only, 7 long/short -
Institutional Ownership and Shareholders 2024-03-31
27 total, 26 long only, 0 short only, 1 long/short -
how many institutions own this stock?
Printing $1.94. IBIO pumper lost over 50% on his latest gamble trying to recover part of his 99.9x% catastrophic loss.
Some too old to learn
DOWN 6% TODAY AS EXPECTED.
GOING LOWER? YES.
IMO
Ouch $2.03 -0.14 (-6.45%)
Stock Analyst threw some more money away on iBIO. Weekend pump backfired. What a dummy.
Oh Lookie. The fake stock analyst from JWP, inc, could apply for a job working for his hero ex-CIO Tommy at i.e. Advising, LLC
'That is' quite a name for a biotech advising company Tommy dreamed up
Maybe the biotech stock analyst at JWP, inc should add an i.e. in front or a bs? He's already down 50% on his latest IBIO pump on top of the 99.9x% bag of IBIO
https://www.linkedin.com/company/ie-advising/people/
EXPECTING IBIO TO TRADE BELOW $1 BEFORE SEPTEMBER
POOR FINANCING DRIVING THIS DOWN AND NO SUPPORT AT ALL
BRAIN DRAINED site to NOT unearth
https://events.jspargo.com/ASCO24/Public/Eventmap.aspx?EventId=776&MapID=990&MapItBoothID=960026&MapItBooth=19131
ALL previous posters on this subject
INCARCERATED again
Followers
|
441
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
27563
|
Created
|
11/13/08
|
Type
|
Free
|
Moderators |
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field,
develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary,
transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.
https://www.ibioinc.com/about/what-we-do
Because the cell line development phase is eliminated, FastPharming offers significant time savings compared to traditional expression platforms.
For instance, iBio produces milligram quantities of protein in as little as 6 weeks, gram quantities in 3 months, and greater than 10g of cGMP material in only 8 months.Additionally,
FastPharming processes are easily scalable, produce high quality product, are cost efficient, deliver improved safety, and facilitate superior glycosylation control.
IBio uses the FastPharming System to quickly produce biotherapeutic and vaccine candidates for unmet medical needs.
In the area of human disease, IBIO-100 targets fibrosis, a leading world-wide cause of organ failure.
IBIO-200 is a virus-like particle (VLP) vaccine designed as a rapid medical countermeasure solution to the COVID-19 outbreak.
The FastPharming platform produces a variety of recombinant products including:
The traditional approach to vaccines is to use live or killed viruses to generate immune responses.
Development, approval, and commercialization of these types of vaccines can take several years, a model that is clearly unfeasible during this pandemic.
New approaches use a reductionist approach by identifying key viral components that can be incorporated into a vaccine that elicits a strong immune response and is also safe and easy to manufacture.1
Such approaches include vaccines that rely on recombinant DNA or messenger RNA (mRNA).
San Diego-based Inovio Pharmaceuticals, the first company to advance a vaccine (INO-4700) against MERS-CoV into human testing,
is developing a DNA-based vaccine against COVID-19, while both Cambridge, Massachusetts-based Moderna and German biotech CureVac are developing mRNA-based vaccines.
There are concerns with many of these approaches, however, particularly DNA and mRNA vaccines.
Questions have been raised about their cold-chain requirements compared with traditional vaccine technology platforms.
These solutions provide great hope but carry significant risk.
At present, six COVID-19 or SARS-CoV-2 phase I clinical trials are listed in clinicaltrials.gov, although there are likely more in the works, as registration in the database is not mandatory until phase II.
Virus-like particles (VLPs) represent a promising alternative to soluble antigens, as their shape, size, repetitive antigen structure,
and geometry have been shown to trigger stronger immune response, both humoral and cellular.2 VLPs are artificial
constructs comprising multiple proteins organized to resemble a virus, but without including any viral genetic material, thereby rendering them non-infectious.
Because they have the components and conformation of the native virus, they can engender stronger and broader immune responses than the antigen itself.
In addition, VLPs can be produced as cost-effectively as other novel platform technologies being used for COVID-19 vaccine development
and do not present additional safety concerns compared with those associated with DNA- and mRNA-based solutions.
iBio has extensive capability in this area, having developed plant-based bioprocesses that generate VLPs with the
same structures as more traditional methods but via more efficient manufacturing routes. VLP platforms like iBio’s are advantageous because,
in addition to obtaining high yields of the individual VLP components, the components automatically self-assemble into a spherical VLP,
simplifying both the upstream and downstream purification processes involved in VLP manufacture.
The recent phase III clinical success of a VLP-based influenza vaccine produced in the N. benthamiana system
(NCT03739112, NCT03301051), both in terms of efficacy and safety, demonstrates the potential for plant-based VLP vaccine development.3
IBIO-200 is iBio’s lead COVID-19 vaccine candidate. iBio uses Woodchuck hepatitis virus and human hepatitis B virus core proteins
fused to COVID-19 receptor-binding motif (RBM), which self-assemble into empty nanoparticles.
The resulting VLPs form 40- to 50-nm diameter nanoparticles. The antigen is displayed in a repetitive structure and geometry,
and the particle is decorated with oligomannose molecules to more closely resemble the structure of naturally occurring viruses.
Oligomannose glycosylation is thought to lead to better cellular uptake of the VLPs by antigen-presenting cells via the mannose receptor.
As with other VLP-derived vaccines, IBIO-200 is designed to interact with immune cells differently than soluble antigens.
The production of IBIO-200 follows standard and highly optimized protocols. Plants are seeded,
germinated, and grown to 5 weeks of age in environmentally controlled grow rooms.
At 5 weeks, plants are vacuum infiltrated with Agrobacterium containing transient plant-specific expression vectors encoding COVID-19 antigen constructs.
After infiltration, the vector drives vaccine expression for 5–7 days; plant material is shredded, and total soluble protein extracted.
Preliminary scalable downstream processes have been designed, including concentration and buffer exchange of clarified extract capture and polishing chromatography.
For evaluation purposes, the first screenings measured expression and protein stability.
Selected candidates will then be injected into mice for an initial immunization study.
IgG response, cytokine profiling, and results of virus neutralization assays will dictate a second candidate screening.
Subsequently, selected candidates will enter toxicology studies in appropriate animal models to support an IND filling.
A lead candidate and a back-up will then be selected for further in vivo efficacy studies.
In parallel, iBio will develop a process that is scalable to cGMP manufacturing, prepare manufacturing documentation, and develop QC release assays.
The FastPharming manufacturing system delivers a tightly controlled particle size, providing considerable quality and scale-up advantages,
as uniform antigen display enables better dose definition and higher product yields.
All of this work will be based on technology proven successful for the clinical development of vaccine candidates in iBio’s U.S.-based,
large-scale production facility with all cGMP, QA, QC, scale-up, and regulatory resources;
the facility is self-contained and secure with highly reliable logistics.
iBio’s FastPharming facility was originally constructed in 2010 with funding from the Defense Advanced Research Projects Agency (DARPA),
part of the U.S. Department of Defense (DoD), which was exploring a range of technologies that could enable faster responses to outbreaks.
Plant-based expression technology won out, and the facility was one of three commercial sites comprising the “Blue Angel” initiative.
As part of the DARPA Blue Angel H1N1 Program, iBio’s facility was designed and built to manufacture kilogram quantities of
recombinant proteins within months versus the historically longer time frames needed for more traditional systems.
Its rapid launch to production has been designed specifically for medical countermeasure responses.
The iBio facility is among the largest biotherapeutic production facilities in the world for the production of recombinant protein in N. benthamiana,
with a current capacity to produce bulk clinical protein at the scale of approximately 500 million doses per year.
iBio technology has been used to produce a number of prophylactic vaccines, including soluble pathogen antigens formulated with adjuvants against anthrax,
H5N1 influenza, H1N1 influenza and hookworm, and a virus-like particle (VLP) formulated with an adjuvant against malaria.
Phase I clinical studies have been completed for all of these vaccine candidates.
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |